Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn
The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease
Read More
Section: Sales
Lilly to acquire Curevo in deal worth $1.5bn
The acquisition will help build Lilly’s infectious disease portfolio
Read More
LEO Pharma to acquire Replay gene therapy platform
The acquisition will advance innovation for patients with rare skin diseases
Read More
Lilly to acquire Centessa in deal worth up to $7.8bn
The companies aim to advance treatments for narcolepsy and other sleep-wake disorders
Read More
Biogen to acquire Apellis in $5.6bn deal
The deal will enhance Biogen’s growth portfolio in immunology and rare disease
Read More